Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-cash Items (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Non-cash Items for 11 consecutive years, with $101.0 million as the latest value for Q1 2026.

  • For Q1 2026, Non-cash Items rose 52.13% year-over-year to $101.0 million; the TTM value through Mar 2026 reached $101.0 million, up 52.13%, while the annual FY2025 figure was $2.9 million, 97.97% down from the prior year.
  • Non-cash Items hit $101.0 million in Q1 2026 for Viking Therapeutics, down from $114.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $49.6 billion in Q2 2023 and bottomed at $1.3 million in Q2 2022.
  • Average Non-cash Items over 5 years is $3.0 billion, with a median of $20.5 million recorded in 2022.
  • Year-over-year, Non-cash Items surged 3880416.43% in 2023 and then crashed 99.55% in 2024.
  • Viking Therapeutics' Non-cash Items stood at $20.5 million in 2022, then soared by 203.24% to $62.2 million in 2023, then surged by 127.13% to $141.3 million in 2024, then dropped by 19.32% to $114.0 million in 2025, then fell by 11.4% to $101.0 million in 2026.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $101.0 million, $114.0 million, and $2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.